Mpar was Ensysce Biosciences’s largest product and service line in fiscal 2024, bringing in $3.09M of $5.21M (59%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Mpar | — | — | $1.29M | $3.09M |
| M P A R | $2.65M | $2.01M | — | — |
| Taap/Oud | $884.62K | — | $937.28K | $2.12M |
| T A A P O U D | — | $516.50K | — | — |
| Total | $3.53M | $2.52M | $2.23M | $5.21M |
Ensysce Biosciences brought in $5.21M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. That was up 133.6% from $2.23M in fiscal 2023. Mpar was the largest at $3.09M (59.2%), ahead of Taap/Oud at $2.12M (40.8%).
Compared with fiscal 2023, Mpar grew 138.7% to $3.09M and Taap/Oud grew 126.6% to $2.12M.
Ensysce Biosciences began breaking out Mpar in fiscal 2023, when it brought in $1.29M. Ensysce Biosciences stopped reporting M P A R ($2.01M in fiscal 2022) and T A A P O U D ($516.50K in fiscal 2022) as separate lines.
Ensysce Biosciences (ENSC) reports its revenue by product and service. In fiscal 2024, Mpar was its largest product and service line, bringing in $3.09M (59.2% of the total), followed by Taap/Oud at $2.12M (40.8%).
Mpar was Ensysce Biosciences' largest product and service line in fiscal 2024, bringing in $3.09M, or 59.2% of the $5.21M total across its two product and service lines.
Mpar grew faster than Taap/Oud in fiscal 2024, up 138.7% from $1.29M to $3.09M. Taap/Oud grew 126.6% to $2.12M.
Every figure comes from Ensysce Biosciences' annual financial filings, as reported. Each line keeps the name Ensysce Biosciences gives it, and years follow its fiscal calendar.
Ensysce Biosciences' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.